Repare Therapeutics (RPTX) Stock Price, News & Analysis

Company Overview

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

Key Stats

• Today's Range: $1.54 to $1.61
• 50-Day Range: $1.37 to $1.59
• 52-Week Range: $0.89 to $4.07
• Volume: 109,963 shs
• Average Volume: 85,727 shs
• Market Capitalization: $68.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.50
• Consensus Rating: Moderate Buy

Repare Therapeutics Stock Analysis - MarketRank™

Repare Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 623rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Repare Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Repare Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Repare Therapeutics are expected to decrease in the coming year, from ($2.04) to ($2.96) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Repare Therapeutics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Repare Therapeutics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Repare Therapeutics has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.23% of the float of Repare Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Repare Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Repare Therapeutics has recently increased by 22.11%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Repare Therapeutics does not currently pay a dividend.

Dividend Growth

Repare Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.23% of the float of Repare Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Repare Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Repare Therapeutics has recently increased by 22.11%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

4 people have searched for RPTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Repare Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.50% of the stock of Repare Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

85.09% of the stock of Repare Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RPTX Stock Analysis - Frequently Asked Questions

How have RPTX shares performed this year?

Repare Therapeutics' stock was trading at $1.31 on January 1st, 2025. Since then, RPTX shares have increased by 21.4% and is now trading at $1.59.

How were Repare Therapeutics' earnings last quarter?

Repare Therapeutics Inc. (NASDAQ:RPTX) announced its earnings results on Friday, August, 8th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.17. The company earned $0.25 million during the quarter, compared to analysts' expectations of $2.50 million.

When did Repare Therapeutics IPO?

Repare Therapeutics (RPTX) raised $126 million in an initial public offering (IPO) on Friday, June 19th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler acted as the underwriters for the IPO.

Who are Repare Therapeutics' major shareholders?

Top institutional investors of Repare Therapeutics include Redmile Group LLC (3.69%), Rangeley Capital LLC (0.83%), Militia Capital Partners LP (0.28%) and XTX Topco Ltd (0.10%). Insiders that own company stock include Bvf Partners L P/Il, Lloyd Mitchell Segal, Michael Zinda and Steve Forte.
View institutional ownership trends.

How do I buy shares of Repare Therapeutics?

Shares of RPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Repare Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Repare Therapeutics investors own include Waste Connections (WCN), American Water Works (AWK), AU Optronics (AUOTY), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and Humana (HUM).

Company Calendar

• Last Earnings: 8/08/2025
• Today: 8/22/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RPTX
• CIK: 1808158
• Web: www.reparerx.com
• Phone: 857-412-7018
• Fax: N/A
• Employees: 180
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Repare Therapeutics: $4.50
• High Price Target: $5.00
• Low Price Target: $4.00
• Potential Upside/Downside: +183.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$84.69 million
• Net Margins: N/A
• Pretax Margin: -43,504.40%
• Return on Equity: -78.25%
• Return on Assets: -66.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.30
• Quick Ratio: 6.30

Sales & Book Value

• Annual Sales: $53.48 million
• Price / Sales: 1.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.57 per share
• Price / Book: 0.62

Miscellaneous

• Outstanding Shares: 42,960,000
• Free Float: 38,019,000
• Market Cap: $68.31 million
• Optionable: Optionable
• Beta: 0.93